Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. Hara (Tokyo, Japan), H. Miyagawa (Tokyo, Japan), J. Araya (Tokyo, Japan), S. Minagawa (Tokyo, Japan), T. Numata (Tokyo, Japan), Y. Umezawa (Tokyo, Japan), A. Asahina (Tokyo, Japan), K. Kuwano (Tokyo, Japan). Effect of anti-IL-17 biologics on KL-6 level and coexisting interstitial pneumoniain patients with psoriasis. 3398

Member's Comments

No comment yet.

Related content which might interest you: Increase in systemic IL-5 is associated with mepolizumab treatment failure in patients with severe asthma Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018 Serum YKL-40 modulation in severe asthma patients treated with Mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Infliximab treatment in patients with interstitial lung disease and rheumatoid arthritis Source: Eur Respir J 2002; 20: Suppl. 38, 587s Year: 2002 Infliximab therapy in interstitial lung disease associated with rheumatoid arthritis Source: Annual Congress 2004 - Fibrosing lung diseases Year: 2004 Serum Amphiregulin expression in severe asthma patients treated with anti-IL-5 therapy Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Rituximab improves interstitial lung disease in rheumatoid arthritis patients Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 Effect of tocilizumab on interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) Source: Virtual Congress 2020 – Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment Year: 2020 Effect of systemic steroid treatment on serum leptin levels in patients with COPD exacerbation Source: Eur Respir J 2005; 26: Suppl. 49, 284s Year: 2005 Effects of infliximab on systemic features in patients with COPD suffering from cachexia Source: Eur Respir J 2006; 28: Suppl. 50, 105s Year: 2006 RA autoantibodies as predictors of rheumatoid arthritis in non-cystic fibrosis bronchiectasis patients Source: Eur Respir J 2014; 44: 1082-1085 Year: 2014 Relationship between MIF and cellular pattern in BAL of patients with sarcoidosis, systemic sclerosis, idiopathic pulmonary fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 377s Year: 2003 Serum concentrations of KL-6 in patients with IPF and lung cancer and serial measurements of KL-6 in IPF patients treated with antifibrotic therapy Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia Year: 2021 Effect of infliximab on lung function and well-being in patients with refractory sarcoidosis Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders Year: 2011 Serum KL-6 identifies ILD patients with a progressive fibrosing phenotype Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020 Prognostic role of CCL18 serum concentrations in patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2007; 30: Suppl. 51, 574s Year: 2007 Autoimmune pulmonary alveolar proteinosis complicated with sarcoidosis: clinical courses and serum levels of anti-GM-CSF autoantibody Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs) Year: 2018 Levels of cytokines and chemokines in BAL fluid in patients with idiopathic interstitial pneumonitis and collagen vascular disease associated interstitial pneumonitis Source: Annual Congress 2011 - The ageing pulmonary interstitium Year: 2011 Effects of infliximab on local and systemic inflammation in patients with COPD suffering from cachexia Source: Eur Respir J 2006; 28: Suppl. 50, 105s Year: 2006 Significant changes in monocyte subsets during infliximab therapy in severe sarcoidosis Source: International Congress 2015 – Sarcoidosis: pathogenesis Year: 2015 Increased CCL18 serum levels in patients with pulmonary fibrosis which reflect disease severity Source: Eur Respir J 2005; 26: Suppl. 49, 21s Year: 2005